Inspire discontinuing epinastine

Inspire (NASDAQ:ISPH) discontinued development of epinastine after the intranasal antihistamine missed the primary endpoint of a statistically significant change vs. placebo in baseline total nasal symptom score (TNSS) in a Phase III trial to treat seasonal allergic rhinitis. The 14-day, double-blind, U.S. trial in 798 patients was evaluating two epinastine concentrations (0.1% and 0.15%). Boehringer Ingelheim (Ingelheim, Germany) granted Inspire exclusive North American rights to the compound in 2006. ...